We are live on
!
Find out more
N
Nuveen Portfolio holdings
AUM
$369B
1-Year Est. Return
31.66%
This Fund
S&P 500
This Quarter
Est. Return
-2.85%
1 Year Est. Return
+31.66%
3 Year Est. Return
+110.02%
5 Year Est. Return
+148.02%
10 Year Est. Return
+492.84%
AUM
$247B
AUM Growth
-$11.7B
(-4.5%)
Cap. Flow
-$1.08B
Cap. Flow
% of AUM
-0.44%
Top 10 Holdings %
Top 10 Hldgs %
21.96%
Holding
3,327
New
107
Increased
1,095
Reduced
1,938
Closed
58
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alnylam Pharmaceuticals
ALNY
|
+$3.11B |
| 2 |
iShares Russell 1000 Growth ETF
IWF
|
+$300M |
| 3 |
Baxter International
BAX
|
+$237M |
| 4 |
American Tower
AMT
|
+$196M |
| 5 |
UnitedHealth
UNH
|
+$193M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$343M |
| 2 |
Meta Platforms (Facebook)
META
|
+$300M |
| 3 |
Microsoft
MSFT
|
+$294M |
| 4 |
Salesforce
CRM
|
+$266M |
| 5 |
Match Group
MTCH
|
+$248M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.83% |
| 2 | Healthcare | 15.1% |
| 3 | Financials | 12.26% |
| 4 | Consumer Discretionary | 11.08% |
| 5 | Industrials | 8.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SPTN
1651
DELISTED
SpartanNash
SPTN
| $7.31M | ﹤0.01% |
251,991
+5,055
| +2% | +$157K |
|
1652
Twist Bioscience
TWST
$7.25B
| $7.31M | ﹤0.01% |
207,540
-2,891
| -1% | -$123K |
|
|
WOW
1653
DELISTED
WideOpenWest
WOW
| $7.28M | ﹤0.01% |
593,470
-305,578
| -34% | -$5.45M |
|
1654
Evolus
EOLS
$501M
| $7.27M | ﹤0.01% |
903,141
-123,487
| -12% | -$1.31M |
|
1655
M/I Homes
MHO
$3.84B
| $7.25M | ﹤0.01% |
200,065
-2,249
| -1% | -$97.1K |
|
1656
Coursera
COUR
$1.54B
| $7.25M | ﹤0.01% |
672,150
-16,850
| -2% | -$223K |
|
1657
Bread Financial
BFH
$4.38B
| $7.23M | ﹤0.01% |
229,827
-7,561
| -3% | -$296K |
|
1658
QCR Holdings
QCRH
$1.7B
| $7.23M | ﹤0.01% |
141,883
+16,090
| +13% | +$900K |
|
1659
Penske Automotive Group
PAG
$14.2B
| $7.21M | ﹤0.01% |
73,263
-5,715
| -7% | -$638K |
|
1660
Nurix Therapeutics
NRIX
$2.65B
| $7.2M | ﹤0.01% |
552,656
+228,071
| +70% | +$3.61M |
|
1661
Innoviva
INVA
$1.48B
| $7.18M | ﹤0.01% |
618,444
-346,071
| -36% | -$4.75M |
|
1662
Axcelis
ACLS
$4.33B
| $7.17M | ﹤0.01% |
118,403
-2,128
| -2% | -$137K |
|
|
SAGE
1663
DELISTED
Sage Therapeutics
SAGE
| $7.17M | ﹤0.01% |
183,043
-3,849
| -2% | -$149K |
|
1664
ICU Medical
ICUI
$4.61B
| $7.16M | ﹤0.01% |
47,572
+3,018
| +7% | +$502K |
|
|
SLCA
1665
DELISTED
U.S. SILICA HOLDINGS, INC.
SLCA
| $7.16M | ﹤0.01% |
653,839
-155,684
| -19% | -$1.98M |
|
1666
Editas Medicine
EDIT
$442M
| $7.15M | ﹤0.01% |
583,747
-2,153
| -0.4% | -$33.5K |
|
|
TBI
1667
Trueblue
TBI
$311M
| $7.11M | ﹤0.01% |
372,789
-44,236
| -11% | -$895K |
|
1668
Papa John's
PZZA
$806M
| $7.09M | ﹤0.01% |
101,281
-20,265
| -17% | -$1.72M |
|
|
BLUE
1669
DELISTED
bluebird bio
BLUE
| $7.09M | ﹤0.01% |
56,002
+39,750
| +245% | +$4.5M |
|
|
RAPT
1670
DELISTED
RAPT Therapeutics
RAPT
| $7.08M | ﹤0.01% |
36,761
+23,089
| +169% | +$4.37M |
|
1671
First Financial Bancorp
FFBC
$3.53B
| $7.07M | ﹤0.01% |
335,233
-6,896
| -2% | -$150K |
|
|
AGR
1672
DELISTED
Avangrid, Inc.
AGR
| $7.06M | ﹤0.01% |
169,194
+11,513
| +7% | +$553K |
|
1673
Upbound Group
UPBD
$1.16B
| $7.05M | ﹤0.01% |
402,775
-168,118
| -29% | -$4.19M |
|
1674
Coherus Oncology
CHRS
$196M
| $7.01M | ﹤0.01% |
729,437
-158,148
| -18% | -$1.6M |
|
1675
WD-40
WDFC
$3.15B
| $6.96M | ﹤0.01% |
39,607
-6,093
| -13% | -$1.14M |
|
Similar funds
VFT
Nuveen's Q3 2022 Portfolio in Review
As of Q3 2022, Nuveen held 3,327 positions worth $247B, down 4.5% from $259B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Trading was light in Q3 2022: portfolio turnover was 5%. Nuveen opened 107 new positions and exited 58, leaving the 3,327-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 24% a quarter earlier, followed by Healthcare and Financials.
- Nuveen's largest Q3 2022 buy was Alibaba: 1,014,906 shares worth $81.2M.
- Nuveen added most to Alnylam Pharmaceuticals in Q3 2022, an estimated $3.11B increase.
- Nuveen's biggest Q3 2022 reduction was Alphabet (Google) Class A, cutting an estimated $343M.
- Nuveen fully exited Atlassian in Q3 2022, selling an estimated $82.9M.
- Nuveen's ten largest holdings make up 22% of its $247B portfolio in Q3 2022.
- Nuveen opened 107 new positions and closed 58 in Q3 2022.
- Nuveen's portfolio value fell 4.5% quarter-over-quarter to $247B.
Based on Nuveen's 13F filing for Q3 2022, filed 14 Nov 2022.